Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Reviews

Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma

Pil Soo Sung

Clin Mol Hepatol. 2022;28(3):333-350. Published online October 19, 2021

Web of Science 23 Crossref 28

DOI: https://doi.org/10.3350/cmh.2021.0308

The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection

Jung Hwan Yu, Soon Gu Cho, Young-Joo Jin, Jin-Woo Lee

Clin Mol Hepatol. 2022;28(3):351-361. Published online November 26, 2021

Web of Science 18 Crossref 19

DOI: https://doi.org/10.3350/cmh.2021.0281

Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound

Junghoan Park, Jeong Min Lee, Tae-Hyung Kim, Jeong Hee Yoon

Clin Mol Hepatol. 2022;28(3):362-379. Published online December 27, 2021

Web of Science 18 Crossref 20

DOI: https://doi.org/10.3350/cmh.2021.0361

Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?

Myung Ji Goh, Dong Hyun Sinn

Clin Mol Hepatol. 2022;28(3):380-395. Published online January 13, 2022

Web of Science 12 Crossref 12

DOI: https://doi.org/10.3350/cmh.2021.0366

Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance

Mina Komuta

Clin Mol Hepatol. 2022;28(3):396-407. Published online January 14, 2022

Web of Science 16 Crossref 17

DOI: https://doi.org/10.3350/cmh.2021.0287

RNA interference as a novel treatment strategy for chronic hepatitis B infection

Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2022;28(3):408-424. Published online February 17, 2022

Web of Science 39 Crossref 44

DOI: https://doi.org/10.3350/cmh.2022.0012

Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases

Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim

Clin Mol Hepatol. 2022;28(3):425-472. Published online July 1, 2022

Web of Science 13 Crossref 14

DOI: https://doi.org/10.3350/cmh.2022.0186

Editorials

Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?

Qian Jin, Rui-Xu Yang, Jian-Gao Fan

Clin Mol Hepatol. 2022;28(3):473-477. Published online June 22, 2022

Web of Science 2 Crossref 2

DOI: https://doi.org/10.3350/cmh.2022.0155

A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease

Seonghwan Hwang, Won Kim

Clin Mol Hepatol. 2022;28(3):478-480. Published online June 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0143

Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults

Byoung Seok Ye

Clin Mol Hepatol. 2022;28(3):481-482. Published online May 16, 2022

Web of Science 1 Crossref 2

DOI: https://doi.org/10.3350/cmh.2022.0097

Original Articles

Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals

Ansel Shao Pin Tang, Kai En Chan, Jingxuan Quek, Jieling Xiao, Phoebe Tay, Margaret Teng, Keng Siang Lee, Snow Yunni Lin, May Zin Myint, Benjamin Tan, Vijay K Sharma, Darren Jun Hao Tan, Wen Hui Lim, Apichat Kaewdech, Daniel Huang, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J Sanyal, Mark Muthiah, Cheng Han Ng

Clin Mol Hepatol. 2022;28(3):483-496. Published online March 2, 2022

Web of Science 48 Crossref 56

DOI: https://doi.org/10.3350/cmh.2021.0406

Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial

Ju Hee Oh, Dae Won Jun, Hye Young Kim, Seung Min Lee, Eileen L. Yoon, Jungwook Hwang, Jung Hwan Park, Hanbi Lee, Wankyu Kim, Hyunsung Kim

Clin Mol Hepatol. 2022;28(3):497-509. Published online April 28, 2022

Web of Science 8 Crossref 6

DOI: https://doi.org/10.3350/cmh.2022.0019

Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults

Seogsong Jeong, Yun Hwan Oh, Seulggie Choi, Jooyoung Chang, Sung Min Kim, Joung Sik Son, Gyeongsil Lee, Joseph C Ahn, Dong Hyeon Lee, Bo Kyung Koo, Won Kim, Sang Min Park

Clin Mol Hepatol. 2022;28(3):510-521. Published online March 17, 2022

Web of Science 30 Crossref 26

DOI: https://doi.org/10.3350/cmh.2021.0332

Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 4

Yang Liu, Xin Zhang, Shuo Chen, Jiazhong Wang, Shuo Yu, Yiming Li, Meng Xu, Harouna Aboubacar, Junhui Li, Tao Shan, Jixin Wang, Gang Cao

Clin Mol Hepatol. 2022;28(3):522-539. Published online May 4, 2022

Web of Science 20 Crossref 20

DOI: https://doi.org/10.3350/cmh.2022.0039

Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study

Ji Hyun Kim, Baek Gyu Jun, Minjong Lee, Hye Ah Lee, Tae Suk Kim, Jeong Won Heo, Da Hye Moon, Seong Hee Kang, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim, Dae Hee Choi

Clin Mol Hepatol. 2022;28(3):540-552. Published online May 6, 2022

Web of Science 4 Crossref 6

DOI: https://doi.org/10.3350/cmh.2021.0169

Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients

Ka Shing Cheung, Lok Ka Lam, Rex Wan Hin Hui, Xianhua Mao, Ruiqi R Zhang, Kwok Hung Chan, Ivan FN Hung, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2022;28(3):553-564. Published online May 11, 2022

Web of Science 12 Crossref 14

DOI: https://doi.org/10.3350/cmh.2022.0082

The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease

Cheng Han Ng, Kai En Chan, Yip Han Chin, Rebecca Wenling Zeng, Pei Chen Tsai, Wen Hui Lim, Darren Jun Hao Tan, Chin Meng Khoo, Lay Hoon Goh, Zheng Jye Ling, Anand Kulkarni, Lung-Yi Loey Mak, Daniel Q Huang, Mark Chan, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J. Sanyal, Mark Muthiah

Clin Mol Hepatol. 2022;28(3):565-574. Published online May 19, 2022

Web of Science 50 Crossref 50

DOI: https://doi.org/10.3350/cmh.2022.0096

Letter to the Editor

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma

Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Hironori Koga, Takuji Torimura

Clin Mol Hepatol. 2022;28(3):575-579. Published online April 21, 2022

Web of Science 6 Crossref 7

DOI: https://doi.org/10.3350/cmh.2022.0047

Snapshot

Microbiome and metabolomics in alcoholic liver disease

Raja Ganesan, Ki Tae Suk

Clin Mol Hepatol. 2022;28(3):580-582. Published online July 1, 2022

Web of Science 6 Crossref 6

DOI: https://doi.org/10.3350/cmh.2022.0171

Viewed By 5015	MAFLD: How is it different from NAFLD?
Viewed By 4843	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4792	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4496	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4466	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 214	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 133	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 119	MAFLD: How is it different from NAFLD?
Cited By 96	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Previous issues